0000000000537858

AUTHOR

Przemysław Podhajski

showing 2 related works from this author

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, p…

2021

The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet treatment (DAPT). Several de-escalation strategies of antiplatelet treatment aiming to enhance safety of DAPT without depriving it of its efficacy have been evaluated so far. We hypothesized that reduction of the ticagrelor maintenance dose 1 month after ACS and its continuation until 12 months after ACS may improve adherence to antiplatelet treatment due to better tolerability compared with the standard dose of ticagrelor. Moreover, improved safety of treatment and preserved anti-is…

Acute coronary syndromemedicine.medical_specialtyELECTRA-SIRIO 2TicagrelorClinical CardiologyPlaceboantiplatelet therapylaw.inventionacute coronary syndrometicagrelorClinical studyPercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineHumansAcute Coronary SyndromeAspirinbusiness.industryMaintenance doseGeneral Medicinemedicine.diseasede-escalationTolerabilityELECTRA-SIRIO 2 ; acute coronary syndrome ; antiplatelet therapy ; de-escalation ; ticagrelorCardiologyCardiology and Cardiovascular MedicinebusinessTicagrelorDe-escalationPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study)

2022

Abstract Aims The coronavirus disease‐2019 (COVID‐19) pandemic has changed the landscape of medical care delivery worldwide. We aimed to assess the influence of COVID‐19 pandemic on hospital admissions and in‐hospital mortality rate in patients with acute heart failure (AHF) in a retrospective, multicentre study. Methods and results From 1 January 2019 to 31 December 2020, a total of 101 433 patients were hospitalized in 24 Cardiology Departments in Poland. The number of patients admitted due to AHF decreased by 23.4% from 9853 in 2019 to 7546 in 2020 (P < 0.001). We noted a significant reduction of self‐referrals in the times of COVID‐19 pandemic accounting 27.8% (P < 0.001), with increase…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Heart failureMedical careLevodopaCOVID‐19Internal medicinePandemicmedicineHumansDiseases of the circulatory (Cardiovascular) systemIn patientPandemicsRetrospective StudiesSARS-CoV-2business.industryMortality rateCarbidopaCOVID-19Original Articlesmedicine.diseaseIn‐hospital mortalityHospitalizationDrug CombinationsIn-hospital mortalityRC666-701Heart failureConcomitantAcute DiseaseOriginal ArticleCardiology and Cardiovascular MedicinebusinessHospital stayESC heart failure
researchProduct